Endralazine

This classification denotes a vasodilating agent with the molecular formula C14H15N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L44741F05P, chemically known as 6-benzoyl-3-hydrazino-5,6,7,8-tetrahydropyrido(4,3-c)pyridazin but generally known as endralazine, which bears US NIH Compound Identifier 47608. European Medicines Agency schedules Endralazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06525MIG. World Health Organization schedules endralazine in its Anatomical Therapeutic Chemical (ATC) Classification. ENDRALAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule endralazine under HS 29339990 and SITC 51577. As of Q4 2014, ENDRALAZINE remains the US FDA Preferred Term for this commodity. Endralazine bears US NLM identifiers UMLS ID C0116074 and NCI Concept Code C77151. SMILES: O=C(N1CCc2nnc(NN)cc2C1)c1ccccc1.